Plasma chemotactic activity during dipyridamole induced myocardial ischemia. 1998

H Wysocki, and M Kazmierczak, and A Wykretowicz, and A Szczepanik, and A Minczykowski
Department of Internal Medicine, Karol Marcinkowski University of Medical Sciences, Poznań, Poland.

BACKGROUND We have previously reported that transient myocardial ischemia induced during exercise or dipyridamole challenge leads to the release of increased amounts of hydrogen peroxide into circulating blood. It would indicate that the temporary functional changes within myocardial cells may constitute there a sterile inflammatory area. Therefore we decided to evaluate the chemotactic properties of plasma in patients undergoing dipyridamole provocative test, as a sign of released inflammatory mediators. The ischemia occurrence was evaluated with 99mTc-SestaMIBI followed by single photon emission computed tomography (SPECT). METHODS Blood samples were obtained from the peripheral vein of 42 patients (18 men and 24 women, mean age 61 years). Plasma chemotactic activity was determined by the use of the Boyden chamber method: immediately before dipyridamole challenge (time 0), 7, and 30 min after drug infusion. The migration of control polymorphonuclear neutrophils towards evaluated plasma samples was estimated. RESULTS Chemotaxis of control PMNs towards plasma isolated from patients without signs of myocardial ischemia 7 min after dipyridamole administration was significantly diminished in comparison with baseline values (p=0.003). Plasma obtained 7 min after dipyridamole infusion from patients manifesting signs of myocardial ischemia by SPECT attracted control PMNs significantly more intensively in comparison to plasma isolated at time 0 (p=0.0005). CONCLUSIONS The obtained results indicate that transient myocardial ischemia induced by dipyridamole challenge leads to generation of chemotactic factors detectable in peripheral blood plasma.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009504 Neutrophils Granular leukocytes having a nucleus with three to five lobes connected by slender threads of chromatin, and cytoplasm containing fine inconspicuous granules and stainable by neutral dyes. LE Cells,Leukocytes, Polymorphonuclear,Polymorphonuclear Leukocytes,Polymorphonuclear Neutrophils,Neutrophil Band Cells,Band Cell, Neutrophil,Cell, LE,LE Cell,Leukocyte, Polymorphonuclear,Neutrophil,Neutrophil Band Cell,Neutrophil, Polymorphonuclear,Polymorphonuclear Leukocyte,Polymorphonuclear Neutrophil
D002634 Chemotaxis, Leukocyte The movement of leukocytes in response to a chemical concentration gradient or to products formed in an immunologic reaction. Leukotaxis,Leukocyte Chemotaxis
D004176 Dipyridamole A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752) Antistenocardin,Apo-Dipyridamole,Cerebrovase,Cléridium,Curantil,Curantyl,Dipyramidole,Kurantil,Miosen,Novo-Dipiradol,Persantin,Persantine,Apo Dipyridamole,Novo Dipiradol
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000787 Angina Pectoris The symptom of paroxysmal pain consequent to MYOCARDIAL ISCHEMIA usually of distinctive character, location and radiation. It is thought to be provoked by a transient stressful situation during which the oxygen requirements of the MYOCARDIUM exceed that supplied by the CORONARY CIRCULATION. Angor Pectoris,Stenocardia,Stenocardias
D014665 Vasodilator Agents Drugs used to cause dilation of the blood vessels. Vasoactive Antagonists,Vasodilator,Vasodilator Agent,Vasodilator Drug,Vasorelaxant,Vasodilator Drugs,Vasodilators,Vasorelaxants,Agent, Vasodilator,Agents, Vasodilator,Antagonists, Vasoactive,Drug, Vasodilator,Drugs, Vasodilator

Related Publications

H Wysocki, and M Kazmierczak, and A Wykretowicz, and A Szczepanik, and A Minczykowski
February 1988, JAMA,
H Wysocki, and M Kazmierczak, and A Wykretowicz, and A Szczepanik, and A Minczykowski
March 1987, JAMA,
H Wysocki, and M Kazmierczak, and A Wykretowicz, and A Szczepanik, and A Minczykowski
July 1987, JAMA,
H Wysocki, and M Kazmierczak, and A Wykretowicz, and A Szczepanik, and A Minczykowski
July 1997, The American journal of cardiology,
H Wysocki, and M Kazmierczak, and A Wykretowicz, and A Szczepanik, and A Minczykowski
October 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
H Wysocki, and M Kazmierczak, and A Wykretowicz, and A Szczepanik, and A Minczykowski
May 1992, General pharmacology,
H Wysocki, and M Kazmierczak, and A Wykretowicz, and A Szczepanik, and A Minczykowski
February 1989, The American journal of cardiology,
H Wysocki, and M Kazmierczak, and A Wykretowicz, and A Szczepanik, and A Minczykowski
June 2021, Pediatrics international : official journal of the Japan Pediatric Society,
H Wysocki, and M Kazmierczak, and A Wykretowicz, and A Szczepanik, and A Minczykowski
August 1989, American heart journal,
H Wysocki, and M Kazmierczak, and A Wykretowicz, and A Szczepanik, and A Minczykowski
October 1996, Journal of the American College of Cardiology,
Copied contents to your clipboard!